La Jolla Pharmaceutical Co (La Jolla Pharmaceutical Co) Short Percentage of Float

View and export this data going back to 1994. Start your Free Trial

What is La Jolla Pharmaceutical Co Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of La Jolla Pharmaceutical Co's Short Percentage of Float

For the Biotechnology subindustry, La Jolla Pharmaceutical Co's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

La Jolla Pharmaceutical Co's Short Percentage of Float Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, La Jolla Pharmaceutical Co's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where La Jolla Pharmaceutical Co's Short Percentage of Float falls into.

La Jolla Pharmaceutical Co (La Jolla Pharmaceutical Co) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » La Jolla Pharmaceutical Co (NAS:LJPC) » Definitions » Short Percentage of Float

Comparable Companies

Traded in Other Exchanges

N/A

Address

201 Jones Road, Suite 400, Waltham, MA, USA, 02451

Website

http://www.ljpc.com

La Jolla Pharmaceutical Co is a biopharmaceutical company. The company's main activity is the discovery, development, and commercialization of innovative therapies that improve patients' life-threatening conditions. The company's portfolio consists of an angiotensin II formulation, which regulates blood pressure; a formulation of hepcidin, an endogenous peptide hormone that regulates iron metabolism; and an antibiotic approved by the U.S. Food and Drug Administration.

Executives

Larry G. Edwards	director, officer: Chief Executive Officer	C/O TETRAPHASE PHARMACEUTICALS, INC., 480 ARSENAL STREET, SUITE 110, WATERTOWN MA 02472
David A Ramsay	director	HALOZYME THERAPEUTICS, INC., 11588 SORRENTO VALLEY ROAD, #17, SAN DIEGO CA 92121
Craig A Johnson	director	C/O PURE BIOSCIENCE, 1725 GILLESPIE WAY, EL CAJON CA 92020
Michael S Hearne	officer: Chief Financial Officer	4747 EXECUTIVE DRIVE SUITE 210 SAN DIEGO CA 92121
Robert Rosen	director	C/O HERON THERAPEUTICS, INC, 4242 CAMPUS POINT COURT, SUITE 200, SAN DIEGO CA 92121
Kevin C Tang	director, 10 percent owner	4747 EXECUTIVE DRIVE, SUITE 210, SAN DIEGO CA 92121
Laura L. Johnson	director	C/O LA JOLLA PHARMACEUTICAL COMPANY, LA JOLLA VILLAGE DRIVE, SUITE 1070, SAN DIEGO CA 92122
Darryl Wellinghoff	officer: Chief Commercial Officer	4550 TOWNE CENTRE COURT SAN DIEGO CA 92121
Lakhmir S Chawla	officer: Chief Medical Officer	1960 KIRBY ROAD, MCLEAN VA 22101
Jennifer Carver	officer: Sr. Vice President, Operations	725 NEWPORT STREET, DENVER CO 80220
James Rolke	officer: Chief Scientific Officer	10182 TELESIS COURT, 6TH FLOOR, SAN DIEGO CA 92121
Perceptive Life Sciences Master Fund Ltd	10 percent owner	C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Joseph Edelman	10 percent owner	C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Perceptive Advisors Llc	10 percent owner	51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
George F Tidmarsh	director, officer: President, CEO & Secretary